PSA Screening Rates Level Off in United States

Share this content:
The USPSTF recommended against PSA testing for men of all ages in 2012.
The USPSTF recommended against PSA testing for men of all ages in 2012.

(HealthDay News) -- Rates of prostate-specific antigen (PSA) screening have leveled off after declining for a number of years in the United States, according to a research letter published online April 24 in JAMA Internal Medicine.

The decline followed recommendations from the U.S. Preventive Services Task Force (USPSTF). In 2008, the USPSTF recommended against PSA screening for men aged 75 or older. Then, in 2012, the group recommended against PSA testing for men of all ages.

In the new study, Stacey Fedewa, Ph.D., director of screening and risk factor surveillance at the American Cancer Society, and colleagues reported that the screening rates appeared to have leveled off. In 2015, the rate of PSA screening in the past year was 32 percent among men age 50 and older.

"Physicians interested in deadopting PSA testing may have done so, closely following the USPSTF recommendation and the media attention that came with it," the authors write. But "other public health organizations still support PSA testing, albeit with shared decision making, and physicians may have chosen to continue to offer PSA testing based on their beliefs about screening and interpretation of clinical trial results."

Abstract/Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs